Physician profile
Peter Rubin
NPI 1164467197
$15,182.67
in general payments reported to CMS, 2019-2025
39 companies · $2,574 in 2025
The $2,574 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,770 · 2020: $792 · 2021: $1,615 · 2022: $1,849 · 2023: $2,420 · 2024: $3,161 · 2025: $2,574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,108 · Education: $48.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,107.84 |
| Education | $48.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,429.26 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,304.58 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $2,044.12 | 2019-2025 | Entyvio, Gattex |
| Qol Medical, LLC | $1,576.94 | 2019-2025 | Sucraid, Sucraid |
| Celgene Corporation | $1,342.71 | 2021-2024 | Zeposia, Reblozyl |
| Janssen Biotech, INC. | $820.20 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $656.74 | 2019-2025 | |
| Ucb, INC. | $519.54 | 2019-2020 | |
| Shire North American Group INC | $296.90 | 2019 | |
| Ferring Pharmaceuticals INC. | $275.02 | 2019-2021 | |
| Lilly USA, LLC | $250.33 | 2024-2025 | Omvoh, Mounjaro, Zepbound |
| Amgen INC. | $191.98 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.65 | 2023-2024 | Cyltezo, Jardiance |
| Merck Sharp & Dohme LLC | $150.71 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Ironwood Pharmaceuticals, INC | $127.53 | 2019-2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.